Doxycycline side effects: what 67,795 FDA adverse event reports show

Doxycycline · 1,201 reaction terms · 384,622 drug–reaction co-reports · data 2026-09-14

Drug class

Tetracycline-class Drug

FDA label (Established Pharmacologic Class)

Who reports

67,795 reports · 72% serious · 6,693 with death outcome · 63% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Doxycycline is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ( 1.1 ) Limitations of Use This formulation of doxycycline has not been evaluated in the treatment or prevention of infections.

FDA label, Indications and Usage

What it is

Doxycycline Capsules 40 mg are hard gelatin capsule shells filled with two types of doxycycline beads (30 mg immediate release and 10 mg delayed release) that together provide a dose of 40 mg of anhydrous doxycycline (C 22 H 24 N 2 O 8 ).

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 2Lab value / disease marker 7Not in label — unassessed 31

What the badges mean

Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,161 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Amyloid arthropathy	55	1,858.1 918.3–3,759.4ROR 1,859.6 · calibrated p 6e-17 ✓	240.3 EB05 191.6 · IC025 +5.8 3/3 methods agree	Not in label — unassessed	serious n=55 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Grip strength	142	496.3 380.1–648.0ROR 497.3 · calibrated p 2e-13 ✓	184.5 EB05 160.4 · IC025 +6.6 3/3 methods agree	Not in label — unassessed	serious n=142 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Congenital hiatus hernia	119	361.8 277.4–472.0ROR 362.5 · calibrated p 3e-12 ✓	161.5 EB05 138.6 · IC025 +6.3 3/3 methods agree	Not in label — unassessed	serious n=119 · ♀ 0% (drug 63%)	not reported in cached trials
C-reactive protein	462	323.7 284.0–368.9ROR 325.9 · calibrated p 5e-12 ✓	156.3 EB05 144.7 · IC025 +6.9 3/3 methods agree	Lab value / disease marker	serious n=462 · ♀ 100% (drug 63%) · 97% clinician	not reported in cached trials
Deep vein thrombosis postoperative	869	247.6 226.5–270.7ROR 250.8 · calibrated p 5e-11 ✓	136.5 EB05 129.1 · IC025 +6.9 3/3 methods agree	Not in label — unassessed	serious n=869 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Anti-cyclic citrullinated peptide antibody	295	246.4 211.4–287.3ROR 247.5 · calibrated p 7e-11 ✓	135.4 EB05 122.9 · IC025 +6.6 3/3 methods agree	Lab value / disease marker	serious n=295 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Jarisch-herxheimer reaction	309	237.3 204.5–275.3ROR 238.3 · calibrated p 1e-10 ✓	132.6 EB05 120.7 · IC025 +6.6 3/3 methods agree	Not in label — unassessed	serious n=294 · ♀ 28% (drug 63%) · 100% clinician	not reported in cached trials
Swollen joint count	106	235.2 182.6–303.1ROR 235.6 · calibrated p 2e-10 ✓	130.0 EB05 110.5 · IC025 +6.0 3/3 methods agree	Not in label — unassessed	serious n=106 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Lupus vulgaris	509	232.4 207.1–260.7ROR 234.1 · calibrated p 1e-10 ✓	131.5 EB05 122.2 · IC025 +6.7 3/3 methods agree	Not in label — unassessed	serious n=509 · ♀ 100% (drug 63%) · 96% clinician	not reported in cached trials
Gastrointestinal mucosal necrosis	55	192.2 137.1–269.4ROR 192.4 · calibrated p 2e-9 ✓	113.6 EB05 90.5 · IC025 +5.4 3/3 methods agree	Not in label — unassessed	serious n=55 · ♀ 0% (drug 63%) · 100% clinician	not reported in cached trials
Swollen joint count increased	1,014	149.3 138.5–160.9ROR 151.6 · calibrated p 4e-9 ✓	100.3 EB05 95.2 · IC025 +6.5 3/3 methods agree	Lab value / disease marker	serious n=1,014 · ♀ 100% (drug 63%) · 96% clinician	not reported in cached trials
Abortion incomplete	553	128.4 116.2–141.7ROR 129.4 · calibrated p 2e-8 ✓	90.3 EB05 84.1 · IC025 +6.2 3/3 methods agree	Not in label — unassessed	serious n=203 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Adjustment disorder with depressed mood	510	104.8 94.8–115.8ROR 105.6 · calibrated p 8e-8 ✓	78.0 EB05 72.4 · IC025 +6.0 3/3 methods agree	Not in label — unassessed	serious n=508 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Rheumatic fever	1,095	103.5 96.7–110.8ROR 105.2 · calibrated p 8e-8 ✓	77.4 EB05 73.6 · IC025 +6.1 3/3 methods agree	Not in label — unassessed	serious n=1,095 · ♀ 100% (drug 63%) · 96% clinician	not reported in cached trials
Retinitis	409	100.4 89.8–112.2ROR 101.0 · calibrated p 1e-7 ✓	75.4 EB05 69.5 · IC025 +6.0 3/3 methods agree	Not in label — unassessed	serious n=409 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Facet joint syndrome	710	89.9 82.7–97.7ROR 90.8 · calibrated p 2e-7 ✓	69.5 EB05 65.3 · IC025 +5.9 3/3 methods agree	Not in label — unassessed	serious n=710 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
X-ray abnormal	373	81.6 72.8–91.5ROR 82.1 · calibrated p 5e-7 ✓	64.4 EB05 59.1 · IC025 +5.7 3/3 methods agree	Lab value / disease marker	serious n=373 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Rheumatoid factor positive	1,183	79.7 74.8–85.0ROR 81.1 · calibrated p 5e-7 ✓	63.3 EB05 60.3 · IC025 +5.9 3/3 methods agree	Lab value / disease marker	serious n=1,183 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Dislocation of vertebra	456	79.7 71.9–88.3ROR 80.2 · calibrated p 6e-7 ✓	63.2 EB05 58.5 · IC025 +5.7 3/3 methods agree	Not in label — unassessed	serious n=456 · ♀ 100% (drug 63%) · 93% clinician	not reported in cached trials
Overlap syndrome	122	66.4 54.6–80.7ROR 66.5 · calibrated p 3e-6 ✓	54.2 EB05 46.6 · IC025 +5.2 3/3 methods agree	Not in label — unassessed	serious n=122 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Duodenal ulcer perforation	1,219	61.5 57.9–65.4ROR 62.6 · calibrated p 3e-6 ✓	51.3 EB05 48.9 · IC025 +5.6 3/3 methods agree	Not in label — unassessed	serious PRR 40.8 · ♀ 100% (drug 63%) · 96% clinician	not reported in cached trials
C-reactive protein abnormal	930	52.4 48.9–56.2ROR 53.1 · calibrated p 9e-6 ✓	44.8 EB05 42.5 · IC025 +5.3 3/3 methods agree	Lab value / disease marker	serious n=928 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Bone erosion	510	51.9 47.3–57.0ROR 52.3 · calibrated p 1e-5 ✓	44.4 EB05 41.3 · IC025 +5.3 3/3 methods agree	Not in label — unassessed	serious n=510 · ♀ 100% (drug 63%) · 97% clinician	not reported in cached trials
Seronegative arthritis	160	51.3 43.4–60.7ROR 51.4 · calibrated p 1e-5 ✓	43.8 EB05 38.4 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=160 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Sleep disorder due to general medical condition, insomnia type	892	49.6 46.3–53.3ROR 50.3 · calibrated p 1e-5 ✓	42.8 EB05 40.5 · IC025 +5.3 3/3 methods agree	Labeled (related wording) related wording	serious n=890 · ♀ 100% (drug 63%) · 97% clinician	not reported in cached trials
Anti-cyclic citrullinated peptide antibody positive	919	45.8 42.8–49.1ROR 46.5 · calibrated p 2e-5 ✓	39.9 EB05 37.8 · IC025 +5.2 3/3 methods agree	Lab value / disease marker	serious PRR 31.9 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Helicobacter infection	1,281	44.4 41.9–47.0ROR 45.2 · calibrated p 3e-5 ✓	38.8 EB05 37.1 · IC025 +5.2 3/3 methods agree	Not in label — unassessed	serious PRR 32.4 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Porphyria acute	172	43.9 37.4–51.5ROR 44.0 · calibrated p 3e-5 ✓	38.3 EB05 33.8 · IC025 +4.9 3/3 methods agree	Not in label — unassessed	serious n=172 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Folliculitis	1,200	40.6 38.2–43.1ROR 41.3 · calibrated p 4e-5 ✓	35.9 EB05 34.2 · IC025 +5.1 3/3 methods agree	Not in label — unassessed	serious PRR 33.3 · ♀ 97% (drug 63%) · 95% clinician	not reported in cached trials
Chronic kidney disease-mineral and bone disorder	120	38.7 32.0–46.8ROR 38.8 · calibrated p 7e-5 ✓	34.3 EB05 29.4 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=120	not reported in cached trials
Muscle injury	872	36.7 34.2–39.3ROR 37.1 · calibrated p 8e-5 ✓	32.8 EB05 31.0 · IC025 +4.9 3/3 methods agree	Not in label — unassessed	serious PRR 28.2 · ♀ 100% (drug 63%) · 95% clinician	not reported in cached trials
Peripheral venous disease	402	34.5 31.2–38.3ROR 34.7 · calibrated p 1e-4 ✓	31.1 EB05 28.6 · IC025 +4.7 3/3 methods agree	Not in label — unassessed	serious n=400 · ♀ 100% (drug 63%) · 92% clinician	not reported in cached trials
Hand deformity	1,271	33.2 31.3–35.2ROR 33.8 · calibrated p 1e-4 ✓	30.0 EB05 28.7 · IC025 +4.8 3/3 methods agree	Not in label — unassessed	serious PRR 25.9 · ♀ 100% (drug 63%) · 96% clinician	not reported in cached trials
Autoimmune disorder	890	31.6 29.5–33.9ROR 32.0 · calibrated p 2e-4 ✓	28.7 EB05 27.2 · IC025 +4.7 3/3 methods agree	Labeled (related wording) related wording	serious PRR 24.4 · ♀ 98% (drug 63%) · 93% clinician	not reported in cached trials
Subcutaneous drug absorption impaired	50	31.2 23.3–41.7ROR 31.2 · calibrated p 3e-4 ✓	28.1 EB05 22.1 · IC025 +4.0 3/3 methods agree	Not in label — unassessed	serious n=48 · ♀ 100% (drug 63%) · 100% clinician	not reported in cached trials
Hyperparathyroidism secondary	224	29.9 26.1–34.3ROR 30.0 · calibrated p 3e-4 ✓	27.3 EB05 24.4 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=224	not reported in cached trials
Lip dry	792	29.9 27.8–32.2ROR 30.2 · calibrated p 3e-4 ✓	27.3 EB05 25.7 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=770 · ♀ 100% (drug 63%) · 94% clinician	not reported in cached trials
Nephrogenic anaemia	405	29.3 26.4–32.4ROR 29.4 · calibrated p 3e-4 ✓	26.7 EB05 24.6 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=405	not reported in cached trials
Drug tolerance decreased	241	29.0 25.5–33.1ROR 29.1 · calibrated p 3e-4 ✓	26.5 EB05 23.9 · IC025 +4.4 3/3 methods agree	Not in label — unassessed	serious n=238 · ♀ 100% (drug 63%) · 90% clinician	not reported in cached trials
Rebound acid hypersecretion	263	28.9 25.5–32.8ROR 29.0 · calibrated p 3e-4 ✓	26.5 EB05 23.9 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=263 · 100% consumer	not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

Concept	Reports	PRR 95% CI	Reading
Interstitial lung disease	1,028	3.33.1–3.5	signal
Liver injury	3,005	3.13.0–3.2	signal
Severe cutaneous reaction	734	3.12.9–3.3	signal
Pancreatitis	784	3.02.8–3.2	signal
Kidney injury	4,040	2.82.7–2.8	signal
Serious infection	6,170	2.52.4–2.5	signal
Tendon disorder	304	2.52.2–2.8	signal
Depression	2,047	2.32.2–2.4	signal
Arrhythmia / qt	1,156	1.81.7–2.0	raised
Anaemia	1,713	1.81.7–1.9	raised
Hyperglycaemia / diabetes	1,944	1.71.7–1.8	raised
Thrombocytopenia	1,189	1.71.6–1.8	raised
Gi bleeding	939	1.61.5–1.7	raised
Venous thromboembolism	1,100	1.61.5–1.7	raised
Hyponatraemia	393	1.51.4–1.7	raised
Opportunistic infection	628	1.41.3–1.5	raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Doxycycline as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

NCT01320033 — Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Ca (N=662, PHASE2; 15 AE terms posted; arms: CD2475/101 40 mg; Doxycycline 100 mg; Placebo)

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Drug ineffective (drug did not work)	5,336	1.3 1.2–1.3ROR 1.3 · calibrated p 0.491	1.3 EB05 1.2 · IC025 +0.3	Reporting / coding artifact	age-adj. PRR 1.5 · serious PRR 2.1	not reported in cached trials
Nausea	5,039	2.0 1.9–2.0ROR 2.1 · calibrated p 0.976	2.0 EB05 1.9 · IC025 +0.9	Labeled adverse reaction exact term	age-adj. PRR 1.7 · serious PRR 2.3	NCT01320033: 14/223 (6.3%) on Doxycycline; 4/222 (1.8%) control
Off label use (used outside approved label)	4,803	1.7 1.7–1.8ROR 1.8 · calibrated p 0.811	1.7 EB05 1.7 · IC025 +0.7	Reporting / coding artifact	age-adj. PRR 1.7 · serious PRR 2.0	not reported in cached trials
Fatigue (tiredness)	4,724	1.9 1.8–1.9ROR 2.0 · calibrated p 0.917	1.9 EB05 1.8 · IC025 +0.9	Not in label — unassessed	age-adj. PRR 1.7 · serious PRR 2.2	not reported in cached trials
Rash	4,186	3.0 2.9–3.1ROR 3.1 · calibrated p 0.584	3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 3.0 · serious PRR 4.0	not reported in cached trials
Diarrhoea (diarrhea)	4,065	2.0 1.9–2.0ROR 2.0 · calibrated p 0.955	2.0 EB05 1.9 · IC025 +0.9	Labeled adverse reaction exact term	age-adj. PRR 1.7 · serious PRR 2.1	not reported in cached trials
Dyspnoea (shortness of breath)	4,053	2.2 2.2–2.3ROR 2.3 · calibrated p 0.902	2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree	Not in label — unassessed	age-adj. PRR 2.0 · serious PRR 2.2	not reported in cached trials
Pain	4,021	2.0 2.0–2.1ROR 2.1 · calibrated p 0.993	2.0 EB05 2.0 · IC025 +1.0	Labeled adverse reaction exact term	age-adj. PRR 2.1 · serious PRR 2.1	not reported in cached trials
Headache	3,953	2.0 1.9–2.0ROR 2.0 · calibrated p 0.953	2.0 EB05 1.9 · IC025 +0.9	Labeled adverse reaction exact term	age-adj. PRR 1.7 · serious PRR 2.5	NCT01320033: 15/223 (6.7%) on Doxycycline; 6/222 (2.7%) control
Vomiting	3,859	2.6 2.5–2.6ROR 2.7 · calibrated p 0.751	2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.3 · serious PRR 2.6 · ♀ 83% (drug 63%)	NCT01320033: 15/223 (6.7%) on Doxycycline; 5/222 (2.3%) control
Drug hypersensitivity	3,745	6.1 5.9–6.3ROR 6.4 · calibrated p 0.129	6.0 EB05 5.8 · IC025 +2.5 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 5.8 · serious PRR 6.3 · ♀ 87% (drug 63%)	not reported in cached trials
Malaise (feeling unwell)	3,008	2.1 2.1–2.2ROR 2.2 · calibrated p 0.964	2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.1 · serious PRR 2.5	not reported in cached trials
Condition aggravated	2,970	3.1 3.0–3.2ROR 3.2 · calibrated p 0.578	3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 2.7 · serious PRR 3.2	not reported in cached trials
Dizziness	2,945	1.8 1.8–1.9ROR 1.9 · calibrated p 0.872	1.8 EB05 1.8 · IC025 +0.8	Not in label — unassessed	age-adj. PRR 1.7 · serious PRR 2.1	not reported in cached trials
Pruritus (itching)	2,937	2.4 2.3–2.5ROR 2.5 · calibrated p 0.823	2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	age-adj. PRR 2.2 · serious PRR 3.5	not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Amyloid arthropathy — n=55, PRR 1,858.1
Grip strength — n=142, PRR 496.3
Congenital hiatus hernia — n=119, PRR 361.8
Deep vein thrombosis postoperative — n=869, PRR 247.6
Jarisch-herxheimer reaction — n=309, PRR 237.3
Swollen joint count — n=106, PRR 235.2
Lupus vulgaris — n=509, PRR 232.4
Gastrointestinal mucosal necrosis — n=55, PRR 192.2
Abortion incomplete — n=553, PRR 128.4
Adjustment disorder with depressed mood — n=510, PRR 104.8

✓ A hand-written Bradford Hill causality assessment exists for this drug: Doxycycline (tetracyclines) ↔ Photosensitivity reaction.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Doxycycline?

In FDA FAERS, the most frequently co-reported reaction terms for Doxycycline are nausea, fatigue, rash, diarrhoea, dyspnoea, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Doxycycline have an FDA boxed warning?

No. The FDA label retrieved for Doxycycline has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Doxycycline causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 0e6b3e17-aeee-4910-8e94-c7ac925b9cca, effective 20250415; matched on openfda.generic_name.exact:"DOXYCYCLINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 1,201 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query DOXYCYCLINE, results-bearing studies sorted by enrollment)

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.